Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-to-target versus routine care maintenance strategies with ustekinumab in Crohn's disease
2016-002918-43Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ustekinumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Status: unknown.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-002918-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002918-43.